New hope for lymphoma patients: experimental drug combo enters final trial phase
NCT ID NCT07355283
First seen Jan 23, 2026 · Last updated Jun 20, 2026 · Updated 20 times
Summary
This Phase 3 trial tests whether adding the experimental drug IMM0306 to standard lenalidomide can improve outcomes for people with follicular lymphoma that has returned or stopped responding to treatment. About 198 participants will be randomly assigned to receive either IMM0306 or a placebo, both with lenalidomide. The study measures how many achieve complete remission and how long they live without the disease worsening.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IMM0306 (Amulirafusp alfa) combined with lenalidomide
What this could lead to
If successful, this combination could offer a new treatment option that helps more people with follicular lymphoma achieve complete remission and delay disease progression.
What could go wrong
This is still an experimental treatment. Even in Phase 3, it may not prove better than existing options, and side effects from the drug combination are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.